Lon S. Schneider on In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned
COMMENT Despite the null cognitive effects after four years of randomized treatment to one of two Aβ antibodies or placebo, DIAN TU substantially advanced trial methods by demonstrating the feasibility of an international network of sites, establishing a trials ...